Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years (Q82674941)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

cervix uterine cancer

1 reference

4

Jacek Wysocki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

Marek Spaczynski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Tino F Schwarz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Achim Schneider

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Andrzej Galaj

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Pamela Perona

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sylviane Poncelet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Toufik Zahaf

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Karin Hardt

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Dominique Descamps

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gary Dubin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

HPV Study Group for Adult Women

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

18 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

581-587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

The carcinogenicity of human papillomavirus types reflects viral evolution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Development and duration of human papillomavirus lesions, after initial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

The causal relation between human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Epidemiology of Genital Human Papillomavirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Delivering on the promise: HPV vaccines and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.10.088

10.1016/J.VACCINE.2008.10.088

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19022320%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference